ACKR3 在乳腺癌、肺癌和脑癌中的作用。

The Role of ACKR3 in Breast, Lung, and Brain Cancer.

机构信息

Departamento de Biología Molecular and Centro de Biología Molecular "Severo Ochoa" (UAM-CSIC), Universidad Autónoma Madrid, Madrid, Spain (M.N., F.M.); Institut de Génomique Fonctionnelle (IGF), Université de Montpellier, CNRS, INSERM, Montpellier, France (A.F., P.M.); Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), Division of Medicinal Chemistry, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (J.B., M.J.S.); and CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain (F.M.).

出版信息

Mol Pharmacol. 2019 Dec;96(6):819-825. doi: 10.1124/mol.118.115279. Epub 2019 Feb 11.

DOI:10.1124/mol.118.115279

PMID:30745320

Abstract

Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.

摘要

最近关于趋化因子受体在疾病中的意义的报告引起了人们对非典型趋化因子受体 3（ACKR3）的关注。这种非典型趋化因子受体在许多癌症类型中过表达，并参与调节肿瘤细胞增殖和迁移、肿瘤血管生成或对药物的耐药性，从而促进癌症的进展和转移的发生。在这里，我们重点讨论 ACKR3 在乳腺癌、肺癌和脑癌中的病理作用的临床意义和潜在机制，并讨论其作为这些疾病的预后因素和潜在治疗靶点的可能相关性。